Direct oral anticoagulants: a review of common medication errors
Stroke and venous thromboembolism continues to be a major cause of morbidity and mortality worldwide. The use of anticoagulation therapy has proven effective in the prevention of stroke and management of thromboembolism; however, initiating treatment may bear clinical burden given the capacity of these agents to cause bleeding. Originally, warfarin has been primarily used, but with the approval of direct oral anticoagulants, therapeutic recommendations have shifted to direct oral anticoagulants for first line therapy for venous thromboembolism for patients without cancer. As compared to warfarin, direct oral anticoagulants are associated with predictable pharmacokinetic profiles, lower bleeding risks, and minimal drug interactions. Complexities in the medication use process can however heighten the risks of causing adverse events. The purpose of this article is to describe common medication errors associated with direct oral anticoagulants, provide practical guidance on the management of direct oral anticoagulants, and suggest strategies to reduce errors. Efforts to minimize medication errors involve the participation of an interdisciplinary team that has standardized policies, risk reduction strategies, and guiding principles to achieve optimal therapeutic outcomes. Current primary literature is not robust in assessment of clinical impact of medication errors associated with DOACs but reports of adverse drug events have been noted. Future studies should be guided to assess clinical outcomes associated with medication errors and identify potential clinical interventions to optimize therapy.
KeywordsAnticoagulation DOAC Medication error Risk reduction
This study was performed without financial support.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Research involving human participants
This article does not contain any studies with human participants performed by any of the authors.
- 2.Bristol-Myers Squibb Company (2016) Eliquis®: highlights of prescribing information. https://packageinserts.bms.com/pi/pi_eliquis.pdf. Accessed 3 Oct 2017
- 3.Boehringer Ingelheim Pharmaceuticals, Inc (2015) [revised 2018]. Pradaxa®: highlights in prescribing information. https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf. Accessed 3 Oct 2017
- 4.Daiichi Sankyo, Co. (2015) Savaysa®: highlights of prescribing information. http://dsi.com/prescribing-information-portlet/getPIContent?productName=Savaysa&inline=true. Accessed 3 Oct 2017
- 5.Janssen Ortho, LLC (2017) Xarelto®: highlights in prescribing information. http://dsi.com/prescribing-information-portlet/getPIContent?productName=Savaysa&inline=true. Accessed 3 Oct 2017
- 6.Bristol-Myers Squibb Company (2017) Warfarin®: highlights of prescribing information. https://packageinserts.bms.com/pi/pi_coumadin.pdf. Accessed 3 Oct 2017
- 7.Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, Florido R, Hucker W, Mehran R, Messé SR, Pollack CV Jr, Rodriguez F, Sarode R, Siegal D, Wiggins BS (2017) 2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulation. J Am Coll Cardiol 70(24):3042–3067CrossRefGoogle Scholar
- 11.January CT, Wann LS, Alpert JS et al (2014) 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 130(23):e199–e267PubMedPubMedCentralGoogle Scholar
- 13.Moore T, Cohen M, Furberg C. Quarter W (2016) Quarter 4. 2017. https://www.ismp.org/sites/default/files/attachments/2018-01/2016Q4_1.pdf
- 36.The five rights: destination without A, Map A. Institute For Safe Medication Practices. http://www.ismp.org/resources/five-rights-destination-without-map. (2007). Accessed 8 Aug 2018
- 38.Institute for Safe Medication Practices. Medication Safety Alert. Volume 18, Issue 25. 12 December 2013Google Scholar
- 41.Portola Pharmaceuticals, Inc, (2018) Andexxa® (coagulation factor Xa (recombinant), inactivated-zhzo) highlights in prescribing information. https://www.andexxa.com/wp-content/uploads/Andexxa%20USPI-v1.4-may2018.pdf. Accessed 12 May 2018
- 43.Boehringer Ingelheim Pharmaceuticals, Inc, (2015) Praxbind®: highlights in prescribing information. https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Praxbind/Praxbind.pdf. Accessed 3 Oct 2017
- 44.Institute for Safe Medication Practices (2017) Medication Safety Self-Assessment® for Antithrombotic Therapy. https://www.ismp.org/assessments/antithrombotic-therapy. Accessed 1 Oct 2017
- 47.Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, Blatchford J, Devenny K, Friedman J, Guiver K, Harper R, Khder Y, Lobmeyer MT, Maas H, Voigt JU, Simoons ML, Van de Werf F, RE-ALIGN Investigators (2013) Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 369(13):1206–1214CrossRefGoogle Scholar